SPIRIVA HANDIHALER

Tiotropium

SPIRIVA HANDIHALER

LAMA DPI

Tiotropium bromide · Boehringer Ingelheim

Clinical Reference

Active Medication & Mechanism

Tiotropium bromide monohydrate LAMA
18 mcg per capsule (delivers 10 mcg from mouthpiece)

Long-acting muscarinic antagonist (anticholinergic). Binds to M1–M3 muscarinic receptors, with slow dissociation from M3 receptors on airway smooth muscle, providing 24-hour bronchodilation.

FDA-Approved Dosing by Indication

// approval varies by strength + age

COPD

1/1 approved regimens

Strength	Population	Dose & Frequency	Total Daily	Status
18 mcg	Adults (≥18 years)	2 inhalations of 1 capsule once daily (entire capsule content) Long-term, once-daily maintenance treatment of bronchospasm associated with COPD, including chronic bronchitis and emphysema. Also reduces COPD exacerbations.	18 mcg	FDA Approved

18 mcg FDA Approved

Pop · Adults (≥18 years)

2 inhalations of 1 capsule once daily (entire capsule content)

Long-term, once-daily maintenance treatment of bronchospasm associated with COPD, including chronic bronchitis and emphysema. Also reduces COPD exacerbations.

Total · 18 mcg

Asthma

0/1 approved regimens

Strength	Population	Dose & Frequency	Total Daily	Status
Any strength	All patients	—	—	Not Approved Spiriva HandiHaler is NOT indicated for asthma. Use Spiriva Respimat for asthma (different product and dose).

Any strength Not Approved

Pop · All patients

—

Total · — Spiriva HandiHaler is NOT indicated for asthma. Use Spiriva Respimat for asthma (different product and dose).

Acute Use

0/1 approved regimens

Strength	Population	Dose & Frequency	Total Daily	Status
Any strength	Acute bronchospasm / rescue	—	—	Not Approved Not for acute bronchospasm. Use a SABA.

Any strength Not Approved

Pop · Acute bronchospasm / rescue

—

Total · — Not for acute bronchospasm. Use a SABA.